
#News for #investors and #media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat adults with advanced ALK-positive non-small cell lung cancer. Learn more: gsk.to/4iQ3zYg

We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: gsk.to/socialmedia

#News for #investors and #media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat adults with advanced ALK-positive non-small cell lung cancer. Learn more: gsk.to/4iQ3zYg

#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) has recommended a new variation for one of our vaccines. Read more: gsk.to/48WRV81

#News for #investors and #media: We’re proud to rank 2nd overall in the Access to Medicines Index, reflecting our ongoing commitment to ensuring vital medicines and vaccines reach people who need them: gsk.to/4zF8ph2 #ATMIndex10

#News for #Investors and #Media: At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD). 🔗 Find out more: gsk.to/3Uct1hi

#Investors: Join GSK’s CEO, Luke Miels, and other members of our leadership team for our Q3 2026 results webcast at 12:00 GMT, 08:00 EDT. $GSK

#Investors and #Media: Please read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures in our Q3 2026 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. gsk.to/3U65izg $GSK

News for #Investors and #Media Watch our CEO, Luke Miels, as he delivers news of our strong Q3 performance and continued momentum ⤵️ Find out more: gsk.to/4zggYib #GSKResults #Earnings


#News for #investors and #media: Today, our licensor Hansoh Pharma presented new Phase 3 data in osteosarcoma, building on ongoing research efforts for patients with difficult-to-treat solid tumours. #ESMO2026 Learn more: gsk.to/3TZ5Yq9

#News for #Investors and #Media: Today, we presented data from one of our immunotherapies used to treat people living with colorectal cancer. Read more: gsk.to/3VTGgUy #ESMO2026

#News for #Investors and #Media: Today, we presented longer-term late-breaking data, marking encouraging progress for people living with ovarian cancer. #ESMO2026 Learn more: gsk.to/3Uh1bAd

#News for #investors & #media: Today marks an important milestone in chronic hepatitis B (CHB), with the U.S. FDA approving a new therapy for people living with the disease. This approval reflects years of research and a continued commitment to advancing innovation in liver disease, where significant unmet need remains. Learn more: gsk.to/4Bisj2s

#News for #Investors and #Media: The US Food and Drug Administration (FDA) has approved a new indication for one of our immunotherapies. Read more: gsk.to/4iwAy2D

#News for #Investors and #Media: Today, we shared the first data for our investigational treatment for extensive-stage small-cell lung cancer in a global population. Learn more: gsk.to/4z38aw4 #ESMO2026

#News for #Investors and #Media: At ESMO 2026, we're showcasing over 20 abstracts from our oncology portfolio and pipeline, underscoring our expansion into solid tumours like lung, gynaecological, gastrointestinal, and GIST. Read more:gsk.to/4dCmnr6 #ESMO2026

Dementia is one of the greatest health challenges facing society today. We're proud to support The BARBARA Alliance in a major new partnership, announced today by UK Government, bringing together academia, charities and industry to help accelerate research. Read more here: gsk.to/4doDhJG